Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of diagnosis-to-treatment interval on the outcome of patients with acute myeloid leukemia.

Annals of hematology·2026

Same author

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis.

Cureus·2026

Same author

Chronic Disseminated Intravascular Coagulation in Patient With Metastatic Gastrointestinal Stromal Tumor: Treating Bleeding With Anticoagulation.

Journal of medical cases·2025

Same author

Pembrolizumab Monotherapy for Early-Stage Triple-Negative Breast Cancer in a Patient With Lynch Syndrome.

JCO precision oncology·2025

Same author

A Multicenter Feasibility Study of a Novel Curriculum for Oncology Trainees Regarding Medical Cannabis.

Journal of the National Comprehensive Cancer Network : JNCCN·2025

Same author

Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.

Oral oncology·2025

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Anaemia with inflammation responding to lenalidomide.

Faysal Haroun¹, Andrew Mener¹, Jacob Elkon²

¹Division of Hematology & Oncology, George Washington University Hospital, Washington DC, USA.

BMJ Case Reports

|October 15, 2016

Summary

A 73-year-old woman with unexplained anemia showed a complete response to lenalidomide treatment. This suggests lenalidomide may treat certain cases of immune-mediated anemia.

Related Experiment Videos

Last Updated: Mar 13, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Area of Science:

Hematology
Immunology
Pharmacology

Background:

Investigating the cause of transfusion-dependent anemia in a 73-year-old woman.
Standard anemia workup, including bone marrow biopsies, was inconclusive.

Observation:

The patient presented with unexplained anemia and elevated inflammatory markers (erythrocyte sedimentation rate and C-reactive protein).
No identifiable inflammatory condition or myelodysplastic syndrome criteria were met.

Findings:

Empirical treatment with lenalidomide, an immunomodulatory drug, resulted in a complete hematologic response.
The patient's anemia resolved following lenalidomide administration.

Implications:

Lenalidomide may be a potential therapeutic option for a specific subset of patients with immune-mediated anemia.
This case highlights the potential role of immunomodulatory agents in managing unexplained anemia with inflammatory features.